EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment

Kristina Kleen iD, Judith Gebauer, Claudia Spix, Lea L Kronziel, Inke König, Katja Baust, Gabriele Calaminus, Thorsten Simon, Barbara Hero, Oliver Zolk, Norbert Graf, Hashim Abdul-Khaliq und 1 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kristina Kleen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany. Hauptthemen laut MEDLINE: Anthracyclines, Cardiomyopathies, Neuroblastoma, Wilms Tumor. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Madeleine Schickedanz Kinderkrebsstiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long‐term childhood cancer survivors (CCS) may develop anthracycline‐induced cardiomyopathy. Our cross‐sectional study focused on the question of whether a central echocardiographic reference assessment is associated with a higher detection rate of cardiac dysfunction in a population‐based cohort of affected children with neuroblastoma or nephroblastoma. We also examined the prevalence of anthracycline‐induced cardiomyopathy and its risk factors. Methods and Patients The cohort of this subproject comprises 370 nephroblastoma or neuroblastoma survivors diagnosed with cancer between 1990 and 2012. At study entry, participants were younger than 18 years old, had been treated with anthracyclines, and had no documented previous cardiac disease. Data were collected via patient questionnaires, cardiologic examinations in the network of adults with congenital heart defects (Erwachsene mit angeborenem Herzfehler [EMAH]) and a reference assessment of the recorded echocardiography.

Results

The prevalence of cardiomyopathy in the study cohort (mean age: 12 years) was 6.3% at a median of 9.1 years after initial cancer diagnosis. Risk factors were an age under 5 years at tumor diagnosis and concomitant treatment with cyclophosphamide or radiation. As a central and novel finding, the detection rates by the EMAH cardiologists and the reference center are similarly high but discrepant.

Discussion

Limitations were mainly due to the low responder rate and incomplete data. This study established a nationwide competence network linking pediatric oncology and cardiology centers across six university hospitals in Germany, enabling data collection on pediatric CCS. Despite lower case numbers compared to adult CCS cohorts, meaningful data were gathered and analyzed.

Conclusion

Cardiac late effects after anthracycline‐based therapy in childhood affect a relevant proportion of long‐term CCS at pediatric age. In order to enable timely diagnosis and treatment, preventive examinations are essential and might benefit from additional central reference assessments. Discrepancy in detection of cardiomyopathy by reference and EMAH cardiologists requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthracyclinesCardiomyopathiesNeuroblastomaWilms TumorKidney NeoplasmsHumansMaleFemaleChildAdolescentChild, PreschoolCross-Sectional StudiesPrevalenceRisk FactorsEchocardiographyInfantCancer Survivors

Substanzen

Anthracyclines

Autor:innen und Institutionen

  • Paediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
  • Medical Clinic 1, University Hospital Schleswig-Holstein, Lübeck, Germany.
  • German Childhood Cancer Registry, Mainz, Germany.
  • Institute of Biometry and Statistics, University of Lübeck, Lübeck, Germany.
  • Paediatric Haematology and Oncology, University Hospital Bonn, Bonn, Germany.
  • Paediatric Oncology and Haematology, University Hospital Cologne, Cologne, Germany.

ORCID-Profile: Kristina Kleen

Förderung

  • Madeleine Schickedanz Kinderkrebsstiftung

Zitieren

APA

Kleen, K., Gebauer, J., Spix, C., Kronziel, L. L., König, I., Baust, K., Calaminus, G., Simon, T., Hero, B., Zolk, O., Graf, N., Abdul-Khaliq, H., & Langer, T. (2025). Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment. Cancer Medicine. https://doi.org/10.1002/cam4.71158

Vancouver

Kleen K, Gebauer J, Spix C, Kronziel LL, König I, Baust K, et al. Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment. Cancer Medicine. 2025. doi:10.1002/cam4.71158

BibTeX
@article{Kleen2025,
  author = {Kleen, Kristina and Gebauer, Judith and Spix, Claudia and Kronziel, Lea L and König, Inke and Baust, Katja and Calaminus, Gabriele and Simon, Thorsten and Hero, Barbara and Zolk, Oliver and Graf, Norbert and Abdul-Khaliq, Hashim and Langer, Thorsten},
  title = {Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71158}
}
Kostenlos starten →